Relacorilant Plus Nab-Paclitaxel Is Becoming a New Standard in Platinum-Resistant Ovarian Cancer
In this article
Previous Taxane Use Did Not Reduce the Survival Benefit
Every Meaningful Survival Gain Matters in Platinum-Resistant Ovarian Cancer
Platinum sensitivity is one of the most fundamental determinants of treatment planning in ovarian cancer. When disease progresses shortly after platinum treatment, the tumor’s biology is considered more resistant, and treatment options narrow. Although single-agent chemotherapies, anti-angiogenic therapies, antibody–drug conjugates, and biomarker-based approaches in selected patients are used in this group, overall survival gains are often modest.
What makes ROSELLA important is that it targets a biological stress pathway supporting chemotherapy resistance rather than simply adding a new cytotoxic drug. Relacorilant aims to weaken tumor cell stress responses and taxane resistance by suppressing glucocorticoid receptor signaling. Its use with nab-paclitaxel is therefore a biologically rational combination.
Brief Concept Note: What Does Platinum-Resistant Ovarian Cancer Mean?
Platinum-resistant ovarian cancermeans recurrence or progression within 6 months after platinum-based chemotherapy. This indicates that the tumor is less sensitive to platinum treatment and makes treatment options more limited. Fallopian tube and primary peritoneal cancers may also be approached similarly to epithelial ovarian cancer biologically and clinically.
How Does Relacorilant Work?
Relacorilant is an oral selective glucocorticoid receptor antagonist. Glucocorticoid receptor signaling can support stress responses, cell survival, and chemotherapy resistance in some tumor cells. By suppressing this pathway, relacorilant aims to make the tumor cell more sensitive to chemotherapy.
This approach differs from simply giving “more chemotherapy.” The aim is to weaken the biological resistance that limits nab-paclitaxel’s effect and increase the clinical value of the same chemotherapy class.
Brief Concept Note: What Are Nab-Paclitaxel and Taxanes?
Nab-paclitaxelis the albumin-bound form of paclitaxel. Taxane-class chemotherapies inhibit cancer cell division by targeting microtubules. Because taxanes such as paclitaxel or docetaxel are widely used in ovarian cancer, most patients with platinum-resistant disease have previously received taxane treatment.
A Phase 3 Study of 381 Patients Previously Treated with Bevacizumab
ROSELLA is a multicenter, open-label, randomized phase 3 study in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. It enrolled 381 patients. Patients had to have received 1–3 previous systemic treatments and bevacizumab in at least one previous treatment.
Patients were randomized 1:1 to relacorilant + nab-paclitaxel or nab-paclitaxel monotherapy. In the experimental arm, relacorilant 150 mg was given orally on the day before, the day of, and the day after nab-paclitaxel infusion. Nab-paclitaxel was administered at 80 mg/m² in the experimental arm and 100 mg/m² in the control arm on days 1, 8, and 15 of a 28-day cycle.
| Item | Relacorilant + nab-paclitaxel | Nab-paclitaxel | Clinical significance |
|---|---|---|---|
| Number of patients | 188 | 193 | A total of 381 patients were randomized. |
| Relacorilant | 150 mg orally; the day before, the same day, and the day after nab-paclitaxel | None | Glucocorticoid receptor signaling was suppressed around chemotherapy. |
| Nab-paclitaxel | 80 mg/m², days 1-8-15, 28-day cycle | 100 mg/m², days 1-8-15, 28-day cycle | The control arm was active single-agent chemotherapy. |
| Patient selection | Platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer; 1–3 previous treatments; prior bevacizumab required | Focused on a patient group with a high treatment need in real-world practice. | |
| Main endpoints | PFS and OS | Both disease control and survival were assessed directly. | |
Brief Concept Note: What Are Bevacizumab, PFS, OS, and HR?
Bevacizumabis an anti-angiogenic antibody targeting the vessel-development signal called VEGF. PFSis the period during which disease remains controlled without progression or death. OSmeans overall survival; it represents the time until death from any cause. HRmeans hazard ratio; a value below 1 indicates a risk reduction favoring the experimental treatment.
Overall Survival: 16,0 Months Versus 11,9 Months
In the final overall survival analysis, median follow-up was 24,8 months . Median overall survival in the relacorilant + nab-paclitaxel arm was 16,0 months, compared with 11,9 months in the nab-paclitaxel monotherapy arm. HR was 0,65, with a %95 confidence interval of 0,51–0,83 and a P value of .0004 .
This result means an approximately %35 relative reduction in the risk of death and an increase in median overall survival of 4,1 months with the addition of relacorilant. An OS gain of this magnitude is clinically meaningful in platinum-resistant ovarian cancer.
PFS Also Improved Significantly
ROSELLA also met its progression-free survival endpoint. According to BICR assessment, median PFS in the relacorilant + nab-paclitaxel arm was 6,5 months, compared with 5,5 months in the nab-paclitaxel arm. HR was 0,70 and the P value was .0076 .
Clinical Significance of the Efficacy Data
- The OS gain is marked: A 4,1-month increase in median OS is meaningful in platinum-resistant ovarian cancer.
- PFS and OS are both positive: Results favored both disease control and survival.
- No biomarker is required: Currently, no specific biomarker selection is needed for benefit from relacorilant + nab-paclitaxel.
- A patient group consistent with real-world practice: All patients had previously received bevacizumab, a substantial proportion had received a PARP inhibitor, and almost all had been exposed to taxanes.
Does Using Nab-Paclitaxel Again Make Sense in a Taxane-Pretreated Patient?
The vast majority of patients with platinum-resistant ovarian cancer have been exposed to taxane-class drugs such as paclitaxel, docetaxel, or nab-paclitaxel in earlier treatment lines. The clinician’s practical question is therefore: if a patient has already received a taxane, will they still benefit from a nab-paclitaxel-based combination?
This is precisely where the value of the ASCO 2026 subgroup analysis emerges. Approximately %99,5 of patients in ROSELLA had previously received taxanes. Nevertheless, the OS advantage of relacorilant + nab-paclitaxel appeared maintained regardless of the taxane-free interval and whether the most recent treatment included a taxane.
Brief Concept Note: What Does Taxane-Free Interval Mean?
The taxane-free intervalmeans the time elapsed since the patient’s last taxane treatment. A short interval may suggest greater tumor resistance to taxanes. In the ROSELLA subgroup analysis, the survival signal favoring the relacorilant combination was maintained both with a taxane-free interval of 6 months or less and with an interval longer than 6 months.
| Subgroup | Relacorilant + nab-paclitaxel | Nab-paclitaxel | HR | Clinical interpretation |
|---|---|---|---|---|
| Taxane-free interval ≤6 months | Median OS 16,7 months | Median OS 11,0 months | 0,60 | A numerical OS advantage favoring the combination even in recently taxane-treated patients. |
| Taxane-free interval >6 months | Median OS 15,7 months | Median OS 12,1 months | 0,66 | Benefit is maintained with a longer taxane-free interval as well. |
| Patients whose most recent previous treatment was a taxane | OS advantage favors the combination | A trend toward shorter survival | 0,67 | Taxane use in the last treatment did not eliminate the benefit. |
| Patients whose most recent previous treatment was not a taxane | OS advantage favors the combination | A trend toward shorter survival | 0,63 | Benefit also continued in those without recent taxane exposure. |
Truecheck Note: Confidence Intervals Are Wide in Some Subgroups
Confidence intervals are wider and statistical uncertainty is greater in small subgroups, such as a taxane-free interval ≤6 months. Subgroup data should therefore be read as a consistency signal supporting the main study result, not as a definitive patient-selection rule on their own.
A Greater Adverse-Effect Burden, but No New Safety Signal
In the final OS analysis, the safety profile of relacorilant + nab-paclitaxel was consistent with previous analyses, with no new safety signal reported. Grade 3 or higher adverse events were reported as %74,5in the combination arm and %59,5 in the nab-paclitaxel monotherapy arm. Serious adverse event rates were reported as %35,1 and %23,7 , respectively.
The most common adverse effects in the combination arm were neutropenia, anemia, fatigue, nausea, and diarrhea. Peripheral neuropathy rates were similar between arms. No relacorilant-related fatal adverse effects or adrenal insufficiency were reported.
Most Common Adverse Effects
- Neutropenia: In the combination arm, any grade %64; grade ≥3 %44.
- Anemia: Any grade %61; grade ≥3 %18.
- Fatigue: Any grade %54; grade ≥3 %9.
- Nausea: Any grade %44; grade ≥3 %4.
- Diarrhea: Any grade %39; grade ≥3 %4.
- Peripheral neuropathy: Reported at similar frequencies in the combination and control arms.
Brief Concept Note: What Are Neutropenia, Adrenal Insufficiency, and Peripheral Neuropathy?
Neutropeniais a reduction in white blood cells important for fighting infections. Adrenal insufficiencyis the inability of the adrenal glands to produce enough cortisol; this is monitored closely because relacorilant targets the glucocorticoid receptor. Peripheral neuropathyis nerve damage involving numbness, tingling, burning, or weakness in the hands and feet, and is an important adverse effect of taxane treatments.
Corticosteroid Requirement Is an Important Practical Limitation
The FDA prescribing information includes a contraindication for patients who need corticosteroids for a life-saving indication, because relacorilant blocks the glucocorticoid receptor. The suitability of this treatment must therefore be assessed carefully in patients with a chronic or frequent need for steroids.
The Search for a New Standard in Platinum-Resistant Ovarian Cancer
For many years, single-agent chemotherapies such as pegylated liposomal doxorubicin, weekly paclitaxel, topotecan, and gemcitabine were used in platinum-resistant ovarian cancer. Adding bevacizumab provided a PFS and response-rate advantage in some patients. More recently, antibody–drug conjugates, immunotherapy combinations, and biomarker-based treatments have expanded the field.
Despite this, achieving a meaningful and reliable improvement in overall survival remains difficult. This is why ROSELLA matters: relacorilant is not a new cytotoxic agent, but a biological modulator targeting the glucocorticoid receptor pathway that may influence chemotherapy resistance. This approach reinforces the idea of “suppressing the stress pathway that prevents chemotherapy from working” rather than “changing chemotherapy” in platinum-resistant ovarian cancer.
| Approach | Underlying rationale | Strength | Limitation | What changes with ROSELLA |
|---|---|---|---|---|
| Single-agent chemotherapies | Cytotoxic agents such as PLD, weekly paclitaxel, topotecan, and gemcitabine | Broad availability and a known safety profile | Limited contribution to response and survival | Nab-paclitaxel is strengthened as an active backbone through biological modulation. |
| Antiangiogenic approach | Suppressing blood vessel growth signaling with bevacizumab | May contribute to response and PFS | Not suitable for everyone; risks of hypertension, proteinuria, thrombosis, and perforation | Prior bevacizumab use was mandatory in ROSELLA, meaning that the study includes later-line patients with a high unmet need. |
| Biomarker-based ADCs | Antibody-drug conjugates selected according to targets such as FRα | Meaningful efficacy in selected patients | Requires a biomarker, and not everyone is eligible | No specific biomarker selection is required for relacorilant + nab-paclitaxel. |
| Glucocorticoid receptor antagonism | Suppressing stress signaling that can support chemotherapy resistance | OS advantage; consistency regardless of prior taxane use | Caution in patients with hematologic toxicity or a need for steroids | Offers a new biological combination strategy in platinum-resistant disease. |
Prior Taxane Treatment Should Not Exclude the Combination
The practical message of the ROSELLA subgroup analysis is clear: a patient's prior taxane use does not automatically eliminate the benefit of relacorilant + nab-paclitaxel. This is highly valuable in real-world practice, because most patients with platinum-resistant ovarian cancer have already been exposed to taxanes.
The FDA approval is also consistent with this clinical framework: relacorilant + nab-paclitaxel is approved for adult patients with platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer who have received 1–3 prior systemic treatments and have used bevacizumab in at least one treatment.
Points to Consider When Selecting Patients
- Number of prior treatments: The FDA approval covers patients who have received 1–3 prior systemic treatments.
- History of bevacizumab: Bevacizumab use in at least one prior treatment is important in the context of the approval.
- Need for steroids: Caution is required when life-saving or chronic corticosteroids are needed.
- Hematologic reserve: Baseline blood counts are important because of the risk of neutropenia and anemia.
- Neuropathy: Peripheral neuropathy should be assessed at baseline because of the nab-paclitaxel backbone.
- Performance status: Patients with ECOG 0–1 were included in the study; real-world tolerability in frail patients should be assessed separately.
How Should We Discuss This with Patients?
“If your disease has become resistant to platinum treatment, treatment options become more limited. Relacorilant is not a drug that acts directly like chemotherapy; it aims to suppress a pathway that can support the tumor's stress response and development of resistance to chemotherapy. When given with nab-paclitaxel, it prolonged survival compared with nab-paclitaxel alone. Having previously received a taxane does not appear to eliminate this benefit completely; however, close monitoring of blood counts, fatigue, diarrhea, neuropathy, and steroid requirements is needed.”
Targeting Biological Stress Pathways in Chemotherapy Resistance
Academic Assessment
The ROSELLA data are a valuable ASCO 2026 result demonstrating that relacorilant + nab-paclitaxel can make a meaningful contribution to overall survival in platinum-resistant ovarian cancer.
Preservation of benefit regardless of prior taxane use makes this treatment more applicable in real-world practice and more clinically meaningful.
Future progress in ovarian cancer treatment will come not only from changing cytotoxic drugs, but also from more rational combinations targeting the biological stress pathways that drive chemotherapy resistance.
The Next Step for Relacorilant Is to Refine Patient Selection
ROSELLA is valuable because it demonstrated an OS advantage without specific biomarker selection. However, future research should identify more precisely which patients benefit most. Topics such as glucocorticoid receptor expression, the tumor microenvironment, inflammatory markers, prior PARP inhibitor use, taxane resistance, and steroid requirements should be investigated in greater detail.
Open Questions
- Is there a biomarker? Can glucocorticoid receptor levels or cortisol-related signatures predict benefit?
- Efficacy after PARP: In which biological subgroups is the benefit more pronounced among patients who previously received a PARP inhibitor?
- Taxane resistance: Which clinical characteristics are associated with actual benefit in patients with a very short taxane-free interval?
- Steroid use: How should alternative strategies be planned for patients who need steroids?
- Sequencing: How will relacorilant + nab-paclitaxel be positioned relative to mirvetuximab soravtansine, bevacizumab-containing regimens, and immunotherapy combinations?
- Quality of life: How will the OS benefit be balanced against the burden of fatigue, hematologic toxicity, and neuropathy?
Truecheck Note
Relacorilant + nab-paclitaxel is a new FDA-approved option in platinum-resistant ovarian cancer. However, because the study included patients with ECOG 0–1, decisions should be individualized for patients with poor performance status, serious comorbidities, a chronic need for steroids, or significant problems with bone marrow reserve.
ROSELLA Reinforces a New Biological Combination Standard in Platinum-Resistant Ovarian Cancer
The final analyses of the phase 3 ROSELLA study showed that relacorilant + nab-paclitaxel significantly prolonged overall survival compared with nab-paclitaxel monotherapy in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Median OS was reported as 16,0 months versus 11,9 months, with HR 0,65 and P=.0004. PFS also favored the combination, at 6,5 months versus 5,5 months.
The subgroup analyses presented at ASCO 2026 show that this survival advantage is maintained regardless of prior taxane use or the taxane-free interval. This finding is particularly important in real-world practice, where a large proportion of patients with platinum-resistant ovarian cancer have already received a taxane.
Rather than trying to overcome conventional chemotherapy resistance solely with a new cytotoxic agent, relacorilant + nab-paclitaxel represents a new approach that targets resistance biology through the tumor's stress response and glucocorticoid receptor signaling. ROSELLA should therefore be interpreted not only as a new FDA approval in platinum-resistant ovarian cancer, but also as a clinical realization of the idea of strengthening chemotherapy biologically.
References
- OncLive. Relacorilant/Nab-Paclitaxel Maintains OS Benefit Irrespective of Prior Taxane Use in Platinum-Resistant Ovarian Cancer. 29 May 2026.
- ASCO 2026 Abstract 5503. Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel vs nab-paclitaxel monotherapy in platinum-resistant ovarian cancer.
- U.S. FDA. FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. 25 March 2026.
- Lorusso D et al. Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial. The Lancet. 2026;407:1513-1524.
- The ASCO Post. Relacorilant Plus Nab-Paclitaxel Improves Overall Survival in Platinum-Resistant Ovarian Cancer. 25 May 2026.
- drozdogan.com. An Innovation in Platinum-Resistant Ovarian Cancer: A Comparison of Relacorilant and Other Treatments. 9 June 2025.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.